Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Conditions:   Ovarian Cancer;   Carcinosarcoma Intervention:   Drug: Pamiparib Sponsor:   Australia New Zealand Gynaecological Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials